Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indian polyvalent antivenom
- Development stage
- Unknown
- Lead developer
- Bharat Serums and Vaccines
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Indian polyvalent antivenom (also known as polyvalent anti-snake venom or ASV) is a life-saving biological therapy used to treat snakebite envenomation in India and neighboring regions. It is a sterile preparation of equine immunoglobulin fragments, specifically F(ab')2, obtained from the plasma of healthy horses hyperimmunized against the venoms of the 'Big Four' medically important venomous snakes of the Indian subcontinent: the Spectacled Cobra (Naja naja), Common Krait (Bungarus caeruleus), Russell's Viper (Daboia russelii), and Saw-scaled Viper (Echis carinatus). The antivenom works by binding to and neutralizing the circulating toxins in the patient's bloodstream, preventing further systemic toxicity such as neuroparalysis, hemorrhage, and venom-induced consumption coagulopathy (VICC). It is manufactured by several Indian pharmaceutical companies and research institutes, including VINS Bioproducts, Bharat Serums and Vaccines, Biological E, and the Serum Institute of India.
- Brand names
- ASVSSnake Venom Antiserum IP
- Other names
- ASVIPAVIndian polyvalent anti-snake venomIndian polyvalent snake antivenomanti-snake venompolyvalent anti-snake venompolyvalent antivenompolyvalent snake antivenom
02
Targets
ECV (Echis carinatus venom)Naja naja venom
Beyond the preview
Go deeper on Indian polyvalent antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indian polyvalent antivenom.